Key Events This Week
7 Sep: Stock opens at Rs.157.25, down 4.84% amid market weakness
8 Sep: Price rebounds 4.99% to Rs.165.10 following initial sell-off
9 Sep: Stock climbs 5.00% to Rs.173.35 after downgrade to Sell and valuation shift
10 Sep: Upgraded to Hold on improved technicals, price rises 4.99% to Rs.182.00
11 Sep: Week closes strong at Rs.190.45, up 4.64%

Choksi Laboratories Ltd Upgraded to Hold on Improved Technicals and Valuation
2026-09-11 08:02:10Choksi Laboratories Ltd has seen its investment rating upgraded from Sell to Hold as of 10 Sep 2026, reflecting notable improvements in its technical indicators and valuation metrics. Despite flat recent financial performance, the company’s stock has demonstrated strong relative returns over the short and medium term, prompting a reassessment of its investment appeal within the healthcare services sector.
Read full news article
Choksi Laboratories Ltd Downgraded to Sell Amid Mixed Technicals and Flat Financials
2026-09-10 08:03:03Choksi Laboratories Ltd, a micro-cap player in the healthcare services sector, has seen its investment rating downgraded from Hold to Sell as of 9 September 2026. This adjustment reflects a nuanced assessment across four critical parameters: quality, valuation, financial trend, and technicals. Despite some attractive valuation metrics and institutional interest, the company’s flat recent financial performance and mixed technical signals have weighed on its overall outlook.
Read full news article
Choksi Laboratories Ltd Valuation Shift Signals Renewed Price Attractiveness
2026-09-10 08:00:33Choksi Laboratories Ltd, a micro-cap player in the Healthcare Services sector, has seen a notable shift in its valuation parameters, moving from a very attractive to an attractive rating. This change reflects evolving market perceptions amid a backdrop of strong price gains and mixed financial metrics, prompting investors to reassess the stock’s price attractiveness relative to its historical and peer benchmarks.
Read full news article
Choksi Laboratories Ltd Upgraded to Hold as Technicals Improve Amid Mixed Financials
2026-08-27 08:03:22Choksi Laboratories Ltd, a micro-cap player in the healthcare services sector, has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement across technical indicators, valuation metrics, and institutional interest despite flat recent financial performance. This upgrade, effective from 26 August 2026, signals cautious optimism amid mixed fundamentals and market underperformance.
Read full news article
Choksi Laboratories Ltd Upgraded to Hold as Technicals Improve and Valuation Attractiveness Increases
2026-08-20 08:03:52Choksi Laboratories Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating upgraded from Sell to Hold as of 19 Aug 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, and financial trends, despite some lingering concerns over long-term fundamentals. The company’s stock price has shown resilience with a 1.10% gain on the day, signalling renewed investor interest amid mixed market conditions.
Read full news article
Choksi Laboratories Ltd is Rated Sell
2026-08-15 10:10:15Choksi Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news articleWhen is the next results date for Choksi Laboratories Ltd?
2026-08-06 23:18:19The next results date for Choksi Laboratories Ltd is scheduled for August 13, 2026....
Read full news article
Choksi Laboratories Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals
2026-08-04 08:07:18Choksi Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The healthcare services company’s technical outlook has improved to mildly bullish, prompting a reassessment of its near-term prospects, even as financial trends and valuation metrics present a mixed picture.
Read full news article





